10-Year Analysis of Adverse Event Reports to the Food and Drug Administration for Phosphodiesterase Type-5 Inhibitors

Journal of Sexual Medicine

Volumn 9, Issue 1, 2012, Pages 265-270

  Lowe, Gregory ^a,b   Costabile, Raymond A ^b  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Adverse Events; Cardiovascular Disease; Death; Food and Drug Administration; Phosphodiesterase Inhibitor

Indexed keywords

SILDENAFIL; TADALAFIL; VARDENAFIL;

ADVERSE DRUG REACTION; BRADYCARDIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY THROMBOSIS; DATA ANALYSIS; DRUG SAFETY; ERECTILE DYSFUNCTION; EXTRASYSTOLE; FOOD AND DRUG ADMINISTRATION; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TACHYCARDIA; UNSPECIFIED SIDE EFFECT;

EID: 84855359486     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2011.02537.x     Document Type: Article

References (22)

1. Eardley I, Donatucci C, Corbin J, El-Meliegy A, Hatzimouratidis K, McVary K, Munarriz R, Lee SW. Pharmacotherapy for erectile dysfunction. J Sex Med 2010;7:524-40.
2. Giuliano F, Jackson G, Montorsi F, Martin-Morales A, Raillard P. Safety of sildenafil citrate: Review of 67 double-blind placebo-controlled trials and the postmarketing safety database. Int J Clin Pract 2009;64:240-55.
3. Shindel A. 2009 update on phosphodiesterase type 5 inhibitor therapy part 2: Updates on optimal utilization for sexual concerns and rare toxicities in this class. J Sex Med 2009;6:2352-64.
4. Vlachopoulos C, Ioakeimidis N, Rokkas K, Stefanadis C. Cardiovascular effects of phosphodiesterase type 5 inhibitors. J Sex Med 2009;6:658-74.
5. Pfizer. August 2011. Available at: (accessed March 12, 2010).
6. Tsertsvadze A, Yazdi F, Fink H, MacDonald R, Wilt T, Soares-Weiser K, Bella A, Deforge D, Garritty C, Ansari M, Sampson M, Daniel R, Moher D. Diagnosis and treatment of erectile dysfunction. Evidence report/technology assessment no. 171. AHRQ publication no. 08(09)-EO16, 2009.
7. Wessells H, Joyce G, Wise M, Wilt T. Erectile dysfunction. J Urol 2007;177:1675-81.
8. Boolell M, Gepi-Attee S, Gingell J, Allen M. Sildenafil, a novel effective oral therapy for male erectile dysfunction. Br J Urol 1996;78:257-61.
9. Goldstein I, Lue T, Padma-Nathan H, Rosen R, Steers W, Wicker P. Oral sildenafil in the treatment of erectile dysfunction. NEJM 1998;338:1397-404.
10. Information for healthcare professionals: sildenafil (marketed as Viagra and Revatio), Vardenafil (marketed as Levitra), Tadalafil (marketed as Cialis). November 2007. Available at: (accessed March 12, 2010).
11. Gratzke C, Angulo J, Chitaley K, Dai Y, Kim N, Paick J, Simonsen U, Uckert S, Wespes E, Andersson KE, Lue TF, Stief CG. Anatomy, physiology, and pathophysiology of erectile dysfunction. J Sex Med 2010;7:445-75.
12. Jackson G, Montorsi P, Adams M, Anis T, El-Sakka A, Miner M, Vlachopoulos C, Kim E. Cardiovascular aspects of Sexual Medicine. J Sex Med 2010;7:1608-26.
13. Batty G, Li Q, Czernichow S, Neal B, Zoungas S, Huxley R, Patel A, de Galen BE, Woodward M, Hamet P, Harrap SB, Poulter N, Chalmers J; ADVANCE collaborative group. Erectile dysfunction and later cardiovascular disease in men with type 2 diabetes. J Am Coll Cardiol 2010;56:1908-13.
14. Chitaley K, Kupelian V, Subak L, Wessells H. Diabetes, obesity, and erectile dysfunction: Field overview and research priorities. J Urol 2009;182:S45-50.
15. Kloner R, Mitchell M, Emmick J. Cardiovascular effects of tadalafil. Am J Cardiol 2003;92:37M-46M.
16. Berenson, Alex, "Sales of Impotence Drugs Fall, Defying Expectations", December 4, 2005. Available at: (accessed December 1, 2011).
17. Muller J. Sexual activity as a trigger for cardiovascular events: What is the risk? Am J Cardiol 1999;84:2N-5N.
18. Cheitlin M. Sexual activity and cardiovascular disease. Am J Cardiol 2003;92:3M-8M.
19. Arruda-Olson A, Mahoney D, Nehra A, Leckel M, Pellikka P. Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease. JAMA 2002;287:719-25.
20. Jackson G, Rosen R, Kloner R, Kostis J. The Second Princeton Consensus on sexual dysfunction and cardiac risk: New guidelines for sexual medicine. J Sex Med 2006;3:28-36.
21. Jackson G, Montorsi P, Cheitlin M. Cardiovascular safety of sildenafil citrate: An updated perspective. Urology 2006;68:47-60.
22. Carson C. Cardiac safety in clinical trials of phosphodiesterase 5 inhibitors. Am J Cardiol 2005;96:37M-41M.